Summary
EW Chart
Edwards Lifesciences: With A Heart Beating Strong And Steady
Edwards Lifesciences is a high-quality, dominant player in structural heart medical devices, with a solid growth history and strong cash generation. The TMTT segment is now the main growth engine, showing rapid expansion, while TAVR growth has plateaued but remains stable. Strategic acquisitions and robust R&D investment position EW for continued innovation and long-term revenue growth above S&P 500 averages.
Edwards' New Late-Breaking Data on Severe AS Expected to Boost Stock
EW's new late-breaking clinical data shows early intervention in AS may slash significant costs and improve patient outcomes.
Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes
PARIS--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new economic and clinical evidence on severe aortic stenosis (AS) presented as a late-breaking clinical trial at EuroPCR 2025, further contributing to the extensive body of research on this disease. The results of a new real-world study of more than 24,000 patients demonstrated that intervening on the disease before symptoms develop reduces the economic and resource burden on the healthcare system and improves patient outco.
East West Banking Corporation Dividends
 EW 16 May 2024 | Other | ₱0.54 Per Share |
| EW 9 May 2023 | Other | ₱0.41 Per Share |
| EW 5 May 2022 | Other | ₱0.4 Per Share |
| EW 4 May 2017 | Other | ₱0.22 Per Share |
| EW 26 Apr 2016 | Other | ₱0.18 Per Share |
East West Banking Corporation Earnings
| 29 Nov 2023 Date | | - Cons. EPS | 0.69 EPS |
| 30 Nov 2016 Date | | - Cons. EPS | 0.34 EPS |
| 31 Aug 2016 Date | | - Cons. EPS | 0.35 EPS |
| 1 Jun 2016 Date | | - Cons. EPS | 0.35 EPS |
| 2 Mar 2016 Date | | - Cons. EPS | 0.31 EPS |
| EW 16 May 2024 | Other | ₱0.54 Per Share |
| EW 9 May 2023 | Other | ₱0.41 Per Share |
| EW 5 May 2022 | Other | ₱0.4 Per Share |
| EW 4 May 2017 | Other | ₱0.22 Per Share |
| EW 26 Apr 2016 | Other | ₱0.18 Per Share |
| 29 Nov 2023 Date | | - Cons. EPS | 0.69 EPS |
| 30 Nov 2016 Date | | - Cons. EPS | 0.34 EPS |
| 31 Aug 2016 Date | | - Cons. EPS | 0.35 EPS |
| 1 Jun 2016 Date | | - Cons. EPS | 0.35 EPS |
| 2 Mar 2016 Date | | - Cons. EPS | 0.31 EPS |
East West Banking Corporation (EW) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has East West Banking Corporation ever had a stock split?
East West Banking Corporation Profile
| Medical - Devices Industry | Healthcare Sector | Mr. Bernard J. Zovighian CEO | XPHS Exchange | PHY223581083 ISIN |
| US Country | 15,800 Employees | - Last Dividend | 1 Jun 2020 Last Split | 27 Mar 2000 IPO Date |
Overview
Edwards Lifesciences Corporation specializes in providing advanced medical technologies tailored to diagnose and treat structural heart diseases and conditions requiring critical care monitoring. The company has a global footprint, offering its state-of-the-art products and solutions across the United States, Europe, Japan, and other international markets. Founded in 1958, Edwards Lifesciences has its headquarters in Irvine, California, and leverages both a direct sales force and a network of independent distributors to reach its market.
Products and Services
- Transcatheter Heart Valve Replacement Products:
Under the Edwards SAPIEN family, these products offer minimally invasive options for replacing aortic heart valves, enabling significant improvements in patient outcomes and recovery times.
- Transcatheter Heart Valve Repair and Replacement Products:
Targeting mitral and tricuspid valve diseases, products under the PASCAL PRECISION and Cardioband names offer advanced solutions for valve repair and replacement, supporting heart function restoration.
- Surgical Structural Heart Solutions:
Edwards provides various surgical solutions including the INSPIRIS aortic surgical valve and the INSPIRIS RESILLA valve, featuring RESILIA tissue and VFit technology for enhanced durability. The KONECT RESILIA and MITRIS RESILIA valve products support complex procedures with pre-assembled tissue valves and innovative designs for better patient outcomes.
- Critical Care Solutions:
The company's critical care portfolio includes hemodynamic monitoring systems such as FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight, designed to measure heart function and fluid status in surgical and ICU settings accurately. The HemoSphere monitoring platform visually displays critical physiological information, and the Acumen Hypotension Prediction Index software utilizes advanced algorithms to predict and alert clinicians of potential dangerous drops in blood pressure.
Contact Information
